Evaxion A (EVAX) Net Margin (2024 - 2025)
Evaxion A (EVAX) posted Net Margin of 61.64% for Q3 2025, up 472185.7% on a QoQ basis from 0.01% in Q2 2025, and up 12578.0% year-over-year from N/an in Q3 2024.
Evaxion A (EVAX) Net Margin (2024 - 2025) Analysis & Trends
Evaxion A's Net Margin history runs 2 years deep, the most recent figure standing at 61.64% for Q3 2025.
- Quarterly Net Margin rose 12578.0% year-over-year to 61.64% in Q3 2025, while the trailing twelve-month figure through Mar 2026 was 0.03% (up 40514.0% YoY) and the FY2025 annual result came in at 102.38%, up 21362.0% from the prior year.
- Net Margin was 61.64% for Q3 2025 at Evaxion A, up from 0.01% in the prior quarter.
- Across five years, Net Margin topped out at 2341.18% in Q1 2024 and bottomed at 4024.68% in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Evaxion A | 25.44 Mn | 25.44 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 61.64% |
| Jun 30, 2025 | -0.01% |
| Dec 31, 2024 | -2,974.59% |
| Sep 30, 2024 | -64.14% |
| Jun 30, 2024 | -4,024.68% |
| Mar 31, 2024 | 2,341.18% |